Inovio Pharmaceuticals Inc (NYSEMKT:INO) Set To Revolutionize Biotech As We Know It


Dallas, Texas 02/24/2014 (FINANCIALSTRENDS) – Inovio Pharmaceuticals Inc(NYSEMKT:INO), one of the leading biotechnology companies in the crowded cutting edge pharmaceutical companies does hold the highest promise. Working extensively on vaccine development, the company has been committed and largely focused on one of the most innovative and highly-advanced platforms for targeted results and has since adopted the – DNA platform.

Joseph Kim, setting the standards of medical drug and vaccine innovation

Inovio Pharmaceuticals Inc(NYSEMKT:INO) is headed by an eminent pharmacology expert, Dr.J.Joshep Kim who holds the company and its inventions as personal achievements. In fact, Inovio Pharmaceuticals Inc(NYSEMKT:INO) has far long been the history of Kim himself as he has been Instrumental in beginning the institutions which has so many academic and clinical accolades to rest on.

According to Dr.Kim, VGX pharmaceuticals the parent of Inovio Pharmaceuticals Inc(NYSEMKT:INO) was begun with great promise along with one Father of DNA vaccine technology- David Wiener, back in 2000. Accordingly, the company made Herceptin, which eventually led to the developmet of antibody technology as we know it today. It was responsible for the development of the class of checkpoint inhibitiors.

Innovative Electroporation solutions

Despite the march of science in evolving new standards of therapy the delivery of the same began to retard progress, until Dr.Weiner in 2006 found the solution in an innovative process called- electroporation. This led to VGX acquiring Advisys, a company which excelled in electroporation technology and later merging in 2009, with Inovio Biomedical, one of the highly-evolved institutions in electroporation engineering and several patents.

Today, Inovio Pharmaceuticals Inc(NYSEMKT:INO) holds its legacy in vivo application development begun at Inovio Biomedical as one of the major technology platforms to develop DNA platform vaccine as well as clinical data base. The development of medical applications with these results  are a pipeline which the company hopes to achieve given nearly nine of them are for preventive cure against many cancers and infection-based diseases.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.